Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
| Autor: | Mario Habek, Magdalena Krbot Skorić, Dragana Šegulja, Dunja Rogić, Ivana Lapić |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
secondary progressive multiple sclerosis
COVID-19 Vaccines Multiple Sclerosis Coronavirus disease 2019 (COVID-19) Antibodies Viral Article chemistry.chemical_compound Immune system SARS-CoV-2 IgG antibody Benzyl Compounds medicine Humans BNT162 Vaccine SARS-CoV-2 business.industry COVID-19 siponimod vaccines Multiple sclerosis Vaccination General Medicine Multiple Sclerosis Chronic Progressive medicine.disease Immunity Humoral Siponimod Neurology chemistry Immunology Azetidines RNA Viral Secondary progressive multiple sclerosis Neurology (clinical) business |
| Zdroj: | Multiple Sclerosis and Related Disorders |
| ISSN: | 2211-0356 2211-0348 |
| Popis: | Objective: The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC). Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19. Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers. Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect